The Food and Drug Administration (FDA) will no longer require premarket review of laboratory developed tests (LDTs), including COVID-19 tests, decline to review emergency use authorization (EUA) request for LDTs. Instead, the FDA will prioritize review of EUAs for point-of-care tests, home collection tests, at-home tests, tests that reduce reliance on test supplies, and high-throughput, widely distributed tests.
FDA Will No Longer Review EUA Requests for COVID-19 Laboratory Developed Tests
More Issues
Wade’s Health Law Highlights for October 27, 2026
Gilead Sciences agreed to pay Texas $45 million to resolve claims that it offered kickbacks to providers that influenced Texas Medicaid prescriptions. The Texas…
Wade’s Health Law Highlights for October 20, 2026
The Eleventh Circuit held in United States v. Chun that the government need only prove a defendant knowingly agreed to accept remuneration for referring…
Wade’s Health Law Highlights for October 13, 2026
A federal grand jury indicted Houston physician Dr. Joseph A. Montes on charges that he and others billed a federal COVID-19 program about $30…